Buradasınız

Anasayfa » Content

Endometriumun Benign, Premalign ve Malign Lezyonlarında Glut-1 ile Ki-67'nin Ayırıcı Tanıdaki Yeri

Value of GLUT-1 and Ki-67 in Differential Diagnosis in Benign, Premalign and Malign Lesions of Endometrium

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: Endometrial carcinoma is the fourth most frequently diagnosed cancer in women. For this reason, the early diagnosis of premalignant lesion of endometrium is very important and it is tried to determine the risk and prognostic factors. The objective of this study was to determine relationship between immunohistochemical markers such as GLUT-1, Ki-67 and benign, premalign, malign lesions of endometrium. Materials and Methods: A total of 100 specimens were retrieved from the archives of the Pathology Department, Firat Medical Center of Firat University. These specimens were containing: 20 proliferative endometrium, 20 secretory endometrium, 20 simple hyperplasia, 20 complex hyperplasia, 20 endometrioid carcinoma. All specimens were stained immunohistochemically with GLUT-1 and Ki-67. Placenta and tonsile tissue was used as positive control specimen for GLUT-1 and Ki-67 respectively. Cells were considered positive only when cytoplasmic staining by GLUT-1 and nuclear staining by Ki-67 was observed. Results: Intensity of GLUT-1 staining shows progresively more staining in endometrioid carcinoma as compared to proliferative endometrium, secretory endometrium and hyperplasia. Mean Ki-67 values were also higher in cases with endometrioid carcinoma (47.96±5.84) compared with those cases with proliferative endometrium (32.90±7.16), secretory endometrium (16.64±9.01), simple hyperplasia (32.28±5.60), complex hyperplasia (35.65±4.33). The relationships between GLUT-1 positivity and Ki-67 PI were found meaningful in similar cases. Conclusion: As in a conclusion, GLUT-1 immunstaining and Ki-67 PI may be useful in distinguishing benign lesions from premalign and malign lesion. ©2006, Fırat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Endometrium karsinomu, kadınlarda görülen karsinomlar arasında dördüncü sırada yer almaktadır. Bu nedenle endometriumun premalign lezyonlarının erken tanısı üzerinde önemle durulmakta ve risk faktörleri ile prognozu etkileyen faktörler belirlenmeye çalışılmaktadır. Çalışmamızda GLUT-1 ve Ki-67 immünohistokimyasal belirleyicilerin, endometriumun benign, premalign ve malign lezyonlarını ayırmadaki önemini belirlemeyi amaçladık. Gereç ve Yöntem: Fırat Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı Laboratuarında tanı almış 20 proliferasyon fazı, 20 sekresyon fazı, 20 basit hiperplazi, 20 kompleks hiperplazi ve 20 endometrioid karsinom olmak üzere toplam 100 olguya immünohistokimyasal yöntemle GLUT-1 ve Ki-67 uygulandı. GLUT-1 için plasenta ve Ki-67 için tonsil dokusuna ait örnekler pozitif kontrol olarak kullanıldı. GLUT-1 ile membranöz boyanma ve Ki-67 ile nükleer boyanma gösteren hücreler pozitif olarak değerlendirildi. Bulgular: GLUT-1 boyanmasında şiddet ve yaygınlığın, proliferasyon fazı, sekresyon fazı ve hiperplazilere göre endometrioid karsinomda belirgin artış gösterdiği belirlendi. Ayrıca Ki-67 proliferasyon indeksinin (PI) de aynı şekilde, proliferasyon fazı (32.90±7.16), sekresyon fazı (16.64±9.01), basit hiperplazi (32.28±5.60) ve kompleks hiperplaziye (35.65±4.33) göre endometrioid karsinomda (47.96±5.84) belirgin artış gösterdiği saptandı. Aynı olgularda GLUT-1 pozitifliği ve Ki-67 PI arasındaki ilişki de anlamlı bulundu. Sonuç: Sonuç olarak endometriumun benign lezyonları ile premalign ve malign lezyonlarının ayırımında GLUT-1 pozitifliğinin ve Ki-67 PI'nin yardımcı olacağı kanısına varıldı.©2006, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-endometriumun-benign-premalign-malign-lezyonlarinda-glut-1-ile-ki-67nin-ayirici-tanidaki-yeri.pdf
  • 2
93-97
  • Turkish

REFERENCES

References: 

1. Tavassoli FA, Devilee P, editor. World Health Organization classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 1 th ed. IARC Pres Lyon 2003: 227-228
2. Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5 th ed. New York: Springer Verlag. 2002: 3-617.
3. Rosai J, editor. Ackerman's Surgical Pathology. 8 th ed. Mosby-Year Book, St Louis 1996: 1392-1437
4. Zimmerman
R
, Burke M, Young N, Solomides C, Bibbo M. Diagnostic utility of GLUT1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer (Cancer Cytopathol) 2002; 96: 53-7
5. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 1992; 54: 911-30.
96
Fırat Tıp
Dergis
i 2006;11(2): 93-97
6. Pardridge W, Boado R, Farrell C. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain-barrier. J Biol Chem 1990; 265: 18035-40.
7. Froehner SC, Davies A, Baldwin SA, Lienhard GE. The blood-nerve barrier is rich in glucose transporter. J Neurocytol 1998; 17:
173-8.
8. Cantuaria G, Magalhaes A, Penalver MO et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of ovary. Gynecologic Oncology 2000; 79: 33¬37
9. Wang BY, Kalir T, Sabo E et al. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial
epithelia. Cancer 2000; 88: 2774-81
10. Trihia H, Murray S, Price K et al. Ki-67 expression in breast carcinoma. Cancer 2003; 97: 1321-31.
11. Vaskivuo TE, Stenbâck F, Karhumaa P et al. Apoptosis and apoptosis-releated proteins in human endometrium. Molecular
and Cellular Endocrinology 2000; 165: 75-83
12. Hayama M, Ota H, Tokı T et al. Cell kinetic study of the endometrium by nonisotopic in situ hybridization for histone H3 messanger RNA and immunohistochemistry for Ki-67 and for estrogen and progesterone receptors. The Anatomical Record
2002; 266: 234-240
13. Tan M, Strunc E, Scholzen T, Gerdes J, Vollmer G. Extracelluler matrix regulates steady-state mRNA levels of the proliferation associated protein Ki-67 in endometrial cancer cells. Cancer
Letters 1999; 140: 145-152
14. Ambros RA. Simple hyperplasia of the endometrium: an evaluation of proliferative activity by Ki-67 immunstaining. Int J
Gynecol Pathol 2000; 19: 206-11.
15. Matsumoto Y, Iwasaka T, Yamasaki F, Sugimori H. Apoptosis and Ki-67 expression in adenomyotic lesions and in the corresponding eutopic endometrium. Obstet Gynecol 1999; 94:
71-7
16. Kendall BS, Ronnett BM, Isacson C et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia and
well-differentiated carcinoma. Am J Surg Pathol 1998; 22: 1012¬9.
17. Cantuaria G, Fagotti A, Ferrandina G et al. GLUT1 Expression in ovarian carcinoma. Cancer 2001; 92: 1144-50
18. Kunkel M, Reichert T, Benz P et al. Overexpression of GLUT1 and increased glucose metabolism in tumors are associated with a
Dağlı ve Özercan
poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97: 1015-24.
19. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of GLUT1 and GLUT3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl
Med Imaging 2004; 31: 5-12
20. Mendez L, Manci N, Cantuaria G et al. Expression of glucose transporter 1 in cervical cancer and its precursors. Gynecologic
Oncology 2002; 86: 138-143
21. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter GLUT-1 in human cancer. Cancer Res 1996; 56: 1164-7.
22. Haber RS, Rathan A, Weiser KR et al. GLUT-1 glucose
transporter expression in colorectal carcinoma: a marker for poor
prognosis. Cancer 1998; 83: 34-40.
23. Cantuaria G, Magalhaes A, Penalver M et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 2000; 79: 33-7.
24. Nisolle M, Casanax-Rous F, Donnez J.
İmmunohistochemica
l anlysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertility And Sterility 1997; 68: 912-9
25. Morsi HM, Leers MPG, Jager W et al. The patterns of expression of an apopitosis related CK-18 neoepitope, the bcl-2 protoonkogene, and the Ki-67 proliferation marker in the normal, hyperplastic and malignant endometrium. Int J Gyn Pathol 2000;
19: 118-126
26. Pizer E, Lax S, Kuhajda F, Pasternack G, Kurman R. Fatty acid synthase expression in endometrial carcinoma. Cancer 1998; 83:
528-37
27. Aksoy F, Seçkin S, Günçe S, Ergül G. Endometriunda hiperplazi ve adenokarsinoma olgularında PCNA ve Ki-67 ile proliferatif aktivite. Ankara Patoloji Bülteni 1998; 15: 16-18
28. Han A, Hovenden S, Rosenblum N, Salazar H. Adenocarcinoma arising in extragonadal endometriosis. Cancer 1998; 83: 1163-9
29. Salvesen HB, Iversen OE, Akslen LA. Identification of high risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res
1998; 4: 2779-2785.

Thank you for copying data from http://www.arastirmax.com